{"name":"Caribou Biosciences, Inc.","slug":"caribou","ticker":"CRBU","exchange":"NASDAQ","domain":"cariboubio.com","description":"Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.","hq":"Berkeley, CA","founded":0,"employees":"97","ceo":"Rachel Haurwitz","sector":"Biotech — Cell & Gene Therapy","stockPrice":1.95,"stockChange":0.09,"stockChangePercent":4.84,"marketCap":"$188M","metrics":{"revenue":11159000,"revenueGrowth":89.7,"grossMargin":0,"rdSpend":109439000,"netIncome":-148125000,"cash":12360000,"dividendYield":0,"peRatio":-1.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"CB-010 patent cliff ($0.0B at risk)","drug":"CB-010","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"CB-011 patent cliff ($0.0B at risk)","drug":"CB-011","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Caribou-sponsored investigational therapy","genericName":"Caribou-sponsored investigational therapy","slug":"caribou-sponsored-investigational-therapy","indication":"Treatment of sickle cell disease","status":"phase_2"}]}],"pipeline":[{"name":"Caribou-sponsored investigational therapy","genericName":"Caribou-sponsored investigational therapy","slug":"caribou-sponsored-investigational-therapy","phase":"phase_2","mechanism":"This investigational therapy targets the CRISPR-Cas12 system to modulate gene expression.","indications":["Treatment of sickle cell disease"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Caribou Biosciences reported its financial results for the fourth quarter and full year 2023, with a net loss of $44.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Caribou Biosciences Enters into Collaboration and Option Agreement with Gilead Sciences","summary":"Caribou Biosciences entered into a collaboration and option agreement with Gilead Sciences to develop CRISPR-based cell therapies for HIV and other diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5VWmlkSnMycl9jN1Q1eDVlRXBSUlRZNkZCSlV0Rko3eVZ0cU1KWlVPakhEbWVQaHAwbXNaaVFjazFPWUJmZnRhMnVNTjJmWXZzWGpHZkhqVk83ZzBtQmNr?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"CRBU Stock Price, Quote & Chart | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill","headline":"CRBU Stock Price, Quote & Chart | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU)","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1vN0ZSV0Y5Nnd2a1NBZVZSeFZNZU1Uakstamd3eDhnZjVkRG84cWlPRGphRm5UTnYyNWd0cDhmTVJZMHNnTDNSQVduRHFqeVF0WnBIdDNJN1JwMDVOaWRyWlBuRkpyOFd5Tl84M2VIYlNvZHlfSGFLRQ?oc=5","date":"2026-02-27","type":"deal","source":"U.S. News Money","summary":"7 Top Gene-Editing Stocks to Buy - U.S. News Money","headline":"7 Top Gene-Editing Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOU0g4SjJqdWdJMHhfaHdCNWIxajNJeGtkcHllVnlwc1lWT1BOakdIYzlKRU9WdkRoV1hsMzJrdldXUGtYYTMwTkZpWlVydnpOM1NTOGgyT09WOW1ZNThNd2NFREFnd3RKc1RwVFM2V2lRel9oLXpjakFWZ0c1blc0U0t1U1lLNTl2RmFyeGp0cXY1YWYwNXlVVHA0S0FsR1lhSDFBaUJPSGNPSWpJZzVablhxM2VPbGE4SHBHTnYzbHVtVHdaVWItTA?oc=5","date":"2026-02-21","type":"deal","source":"The Globe and Mail","summary":"Caribou Biosciences (CRBU) Receives a Buy from Citi - The Globe and Mail","headline":"Caribou Biosciences (CRBU) Receives a Buy from Citi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE94RTBzRDcwN1JheXd4Ty1KWG9aTlJ6cWpseEtfLTlvU21lTG9UNzFlM1RaSlFKV0hRN1VPNnNDNEh5TFE2OFAyYkpwVHVfbll5dlR3Y3Raby03dw?oc=5","date":"2026-02-14","type":"pipeline","source":"Intellectia AI","summary":"CRBU PE Ratio & Valuation, Is CRBU Overvalued - Intellectia AI","headline":"CRBU PE Ratio & Valuation, Is CRBU Overvalued","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOODlBMHhna3haZWJKdTkyZGpsT1Z2NkxnS0dsekI0cHNJRjBXUG00Q3dPTGNQZWZOQkZaSkpnSTlLNzRURy1WRmtUMm5VYUYtd2Z3X25fbEFNeThuNXlyeENfSVR2TlJQX3A3c3pkeDJ6ZS1vd2FNcjdWY0RhTUlaUVRIQmp6Q1RQaWRqemtZNW1iZnJhLVdRc01HNm1oTEFoVndoRG16OXQ?oc=5","date":"2026-02-12","type":"pipeline","source":"investingnews.com","summary":"Caribou Biosciences to Participate in Upcoming Investor Conferences - investingnews.com","headline":"Caribou Biosciences to Participate in Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQdloydmJfbEc1MlhsU3JRcklib0lxZWlWYzhNYmxnajdLeHp5WHBaUnRZVlN2UXRuS2tYY2ZvV0lHdklVaFlOUjQ4WmNnSW1IYmxseE5LaXRITzdqX01tWTNGQ3E5UFp4RTM1aWVxclBFTzdaSDBMdnl1cUNCZVlWU0dJTjh4Z25iemtnNVFtaS0xbHZG?oc=5","date":"2025-11-03","type":"trial","source":"The Pharma Letter","summary":"Caribou Bio leaps on early data for vispa-cel - The Pharma Letter","headline":"Caribou Bio leaps on early data for vispa-cel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE91RTdrM0sxR2FYZUV0WktVTEs3cmhLTVNob2hEVXVBUzFzMENCM2tTSnpEZzJJbEZrcXgtX1V2QkMtVkRnRUVBVXYtclhHbjBKTmxhZ3lMeFRvQWlpSHBDSjNB?oc=5","date":"2025-08-16","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Caribou Biosciences, Inc. (CRBU) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Caribou Biosciences, Inc. (CRBU) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9DbHA3ampEbEJnY2dBLVNtUWhRRlZ5QUNnZkhWWVJtNVJLTDhrcHltRUNtQ1FrRlZmeU51djBzUDl2eDhFd3RCMDlOU19xczhua0hj?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"VTYX Stock Price, News & Analysis - Stock Titan","headline":"VTYX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPcWxFSnlrWVp3Um13cXQ3dHZWZlJJcjVDUDU1Sy04b21ROTlDR3dTTk4yV3lFNTBRMC1kM0o5WkxxUkNxWWhUV0ZmYl9qTDRFSE1OeU55OGdCUURydEMtWkZCYzBoNW9TX3pFbUJrQlZvc0M2dU5KSnBWTVAzMWFMNFZRNFhrd1pnelBuVGt6MEVfUnVRSV8tSXl3QkdhN1hQc1BYSmNwbWRWN1VlM0xCcThkd1BFTVB4VFYzV3U4cXBWWHRLSFV5dTNsVXB2aVJIeFhfcUQySFBTR1BDa2RPQkNCM1lXWXVEN2dzTkRJYk5vYlMycjlLLWVFN0RxR1VIYTJ1ei1abnVER29QV0RjTg?oc=5","date":"2025-02-10","type":"pipeline","source":"PR Newswire","summary":"Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact The Gross Law Firm about pending Class Action - CRBU - PR Newswire","headline":"Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact The Gross Law Firm about pending Class Ac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQUHBUSVR6VHdhdzd4OFRpbDNINWswcE9RQWRQaUpHa2lMMy1hckVjamJlRVg0VmNVWmE1d3AxUVNfS28yOXhwVU9JanVHWTA2RklHdTJFaTlJRXIwQmZ5VzFpNVp6N1pZMU5fQnJkOEp5Ujc2TGFoWVZKRDcxQ0tKS2NILTI?oc=5","date":"2024-12-30","type":"pipeline","source":"Yahoo Finance","summary":"Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance","headline":"Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9HaUh4ci1JS1pCQ3VsX2FNWE5mOXhpSmFVRllROXg5eGVVYVo4bFFrZXg3ZlRCM1J2TGd2NE1DMGtGbTU3TnpHUE56NDJoOGZy?oc=5","date":"2023-11-16","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5ka09VVHU3cnRQeW5OSmRCdWNYRklVb202dHc3dFp4TFJ5MUxHbGY5RU1wWFFPOXM1STZqcUR3MXoyeTFPMDdUT2xhNk1yUlRPRWstUWw5RkRLMHZ0Q0ZkRWNmVzJmWWdqNGl3cnI0OUMwQjVuXy1MVQ?oc=5","date":"2022-09-07","type":"pipeline","source":"Zacks Investment Research","summary":"What is the current Price Target and Forecast for Caribou Biosciences (CRBU) - Zacks Investment Research","headline":"What is the current Price Target and Forecast for Caribou Biosciences (CRBU)","sentiment":"neutral"}],"patents":[{"drugName":"CB-010","drugSlug":"cb-010","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"CB-011","drugSlug":"cb-011","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Intellia Therapeutics"],"therapeuticFocus":["Oncology","Autoimmune Diseases"],"financials":{"source":"sec_edgar","revenue":11159000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":11159000,"period":"2025-12-31"},{"value":9994000,"period":"2024-12-31"},{"value":34477000,"period":"2023-12-31"},{"value":13851000,"period":"2022-12-31"},{"value":9598000,"period":"2021-12-31"},{"value":3977000,"period":"2021-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":109439000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-148125000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":12360000,"cashHistory":[],"totalAssets":175367000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.95,"previousClose":1.86,"fiftyTwoWeekHigh":3.54,"fiftyTwoWeekLow":0.71,"fiftyTwoWeekRange":"0.71 - 3.535","fiftyDayAverage":1.76,"twoHundredDayAverage":1.88,"beta":2.46,"enterpriseValue":67632192,"forwardPE":-1.3,"priceToBook":1.51,"priceToSales":16.84,"enterpriseToRevenue":6.06,"enterpriseToEbitda":-0.52,"pegRatio":0,"ebitda":-130273000,"ebitdaMargin":0,"freeCashflow":-69796752,"operatingCashflow":-110992000,"totalDebt":27227000,"debtToEquity":22.3,"currentRatio":5.71,"returnOnAssets":-34.3,"returnOnEquity":-79,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":11.12,"targetHighPrice":32,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":9.7,"institutionHeldPercent":37.7,"sharesOutstanding":96637202,"floatShares":92267268,"sharesShort":7057089,"shortRatio":4.88,"shortPercentOfFloat":7.3,"epsTrailing":-1.59,"epsForward":-1.5,"revenuePerShare":0.12,"bookValue":1.28,"officers":[{"age":39,"name":"Dr. Rachel E. Haurwitz Ph.D.","title":"Co-Founder, CEO, President & Director"},{"age":55,"name":"Mr. Timothy P. Kelly M.B.A.","title":"Chief Technology Officer"},{"age":70,"name":"Ms. Barbara G. McClung Esq., J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":43,"name":"Mr. Sriram  Ryali M.B.A.","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Ryan  Fischesser","title":"Interim Principal Accounting Officer & Controller"},{"age":null,"name":"Ms. Reigin  Zawadzki","title":"Chief People Officer"},{"age":49,"name":"Ms. Ruhi A. Khan M.B.A.","title":"Chief Business Officer"},{"age":51,"name":"Dr. Tina  Albertson M.D., Ph.D.","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://cariboubio.com","phone":"510 982 6030"}}